Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 25, 2015 14:38:11 GMT -5
You know, as i read this it occurred to me; did Sanofi host the "early adopters" in California so they could report their findings to Google/Alphabet without drawing too much attention? Perhaps this has been discussed and I missed it so forgive me if that's the case. We now have a very long MNKD investor,(odehrafe) claiming that it was Sanofi that chose the new CEO. I was wondering if one or all of the companies listed played a part in picking the new CEO, it does make sense. I hope the MNKD mystery is solved soon !! Merry Christmas to all how long? lol..very long.. how long would very long be? odehrafe? who where?
|
|
|
Post by lakers on Dec 25, 2015 15:05:51 GMT -5
Looking ahead to 2016, we’re optimistic about these seven diabetes products potentially hitting the market in the next 12 months. asweetlife.org/feature/7-new-diabetes-products-to-look-for-in-2016/Insulet’s Omnipod Phoenix PDM Insulin Pump Photo courtesy of Diabetes Mine At the ADA Scientific Sessions in Boston this June, Insulet teased the crowd with a first look at the next generation controller for their popular patch insulin pump, the Phoenix PDM (Personal Diabetes Manager). The chunky plastic PDM controllers we saw in the UST200 and UST400 models will give way to a sleek, sexy color touchscreen interface. The Phoenix will be thinner than the UST400, black in color, and resemble a smartphone. Though the Phoenix will be Bluetooth-enabled, this PDM will not yet be integrated with the Dexcom G5, though we should see that product quickly on its coattails given that value-added capability. When might we see the Phoenix rise? In their Q3 earnings call on 5 November, Insulet CEO Patrick Sullivan said they are “on track to submit our Phoenix PDM product to the FDA in the middle of next year, and we would expect to have that on the market or approved by the end of next year.”
|
|
|
Post by rockstarrick on Dec 25, 2015 15:25:54 GMT -5
We now have a very long MNKD investor,(odehrafe) claiming that it was Sanofi that chose the new CEO. I was wondering if one or all of the companies listed played a part in picking the new CEO, it does make sense. I hope the MNKD mystery is solved soon !! Merry Christmas to all how long? lol..very long.. how long would very long be? odehrafe? who where? Let me rephrase that, "longer than me" as I think odehrafe was around when I jumped on the MNKD train. He/she has my respect.
|
|
|
Post by EveningOfTheDay on Dec 25, 2015 15:32:39 GMT -5
OK, I play just for fun.
So Odehrafe bases her claim, if it is a claim and not merely more speculation, on exactly what?
Please understand I am not challenging neither supporting his/her claim. I am just curious as to it.
|
|
|
Post by suebeeee1 on Dec 25, 2015 15:36:53 GMT -5
Rick,
You've been around long enough to trust. I'll take the odehrafe at your word even though he doesn't show up anywhere in the membership base. I would like more information as to where he gets his information about the Sanofi involvement.
This is all very curious. If indeed SNY is the force behind the new CEO, the dots could well be connecting before our eyes. It would make me more certain if the trials have been completed (or even started) and we were able to re-launce with all the new labeling. My guess is that behind the scenes, there has been much more action than we know.
If we are lucky, it will all be revealed within the next few weeks. Of course, I really hate depending upon luck!
|
|
|
Post by EveningOfTheDay on Dec 25, 2015 15:44:23 GMT -5
Rick, You've been around long enough to trust. I'll take the odehrafe at your word even though he doesn't show up anywhere in the membership base. I would like more information as to where he gets his information about the Sanofi involvement. This is all very curious. If indeed SNY is the force behind the new CEO, the dots could well be connecting before our eyes. It would make me more certain if the trials have been completed (or even started) and we were able to re-launce with all the new labeling. My guess is that behind the scenes, there has been much more action than we know. If we are lucky, it will all be revealed within the next few weeks. Of course, I really hate depending upon luck! I could not agree more with what I highlighted in red. As to being lucky... well, luck is not something that has been smiling on MNKD longs for quite a while now, so I rather not count on it too much... or at all, to be honest.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 25, 2015 15:50:19 GMT -5
Rick, You've been around long enough to trust. I'll take the odehrafe at your word even though he doesn't show up anywhere in the membership base. I would like more information as to where he gets his information about the Sanofi involvement. This is all very curious. If indeed SNY is the force behind the new CEO, the dots could well be connecting before our eyes. It would make me more certain if the trials have been completed (or even started) and we were able to re-launce with all the new labeling. My guess is that behind the scenes, there has been much more action than we know. If we are lucky, it will all be revealed within the next few weeks. Of course, I really hate depending upon luck! unfortunately trials cannot be speculated. they should be listed in clinicaltrials.gov
|
|
|
Post by sportsrancho on Dec 25, 2015 18:08:32 GMT -5
how long? lol..very long.. how long would very long be? odehrafe? who where? Let me rephrase that, "longer than me" as I think odehrafe was around when I jumped on the MNKD train. He/she has my respect. oxotnik1 and odehrafe seem to be connected to SNY in some way or know people who are. They knew about the meeting in Del Mar. But not from the T1's. Someone in side SNY, so I tend to believe that SNY did pick the CEO. Over the years you get a feel for who is full of BS and who isn't. Rock is really good at weeding out the truth:-). Merry Xmas all, this will be an exciting new year! sports
|
|
|
Post by rockstarrick on Dec 25, 2015 18:53:40 GMT -5
Let me rephrase that, "longer than me" as I think odehrafe was around when I jumped on the MNKD train. He/she has my respect. oxotnik1 and odehrafe seem to be connected to SNY in some way or know people who are. They knew about the meeting in Del Mar. But not from the T1's. Someone in side SNY, so I tend to believe that SNY did pick the CEO. Over the years you get a feel for who is full of BS and who isn't. Rock is really good at weeding out the truth:-). Merry Xmas all, this will be an exciting new year! sports Thanks Sports, Merry Christmas
|
|
|
Post by kball on Dec 25, 2015 19:03:37 GMT -5
Let me rephrase that, "longer than me" as I think odehrafe was around when I jumped on the MNKD train. He/she has my respect. oxotnik1 and odehrafe seem to be connected to SNY in some way or know people who are. They knew about the meeting in Del Mar. But not from the T1's. Someone in side SNY, so I tend to believe that SNY did pick the CEO. Over the years you get a feel for who is full of BS and who isn't. Rock is really good at weeding out the truth:-). Merry Xmas all, this will be an exciting new year! sports His post was the one i remember reading about meeting in Del Mar first also. Confirmed about a week after he posted by someone else i trust. SO much BS, its a relief to get reliable tidbits from the very few seemingly non BS posters on ymb (who also happen to be less active and only post when something of value is learned to share)
|
|
|
Post by rockstarrick on Dec 25, 2015 21:10:42 GMT -5
Rick, You've been around long enough to trust. I'll take the odehrafe at your word even though he doesn't show up anywhere in the membership base. I would like more information as to where he gets his information about the Sanofi involvement. This is all very curious. If indeed SNY is the force behind the new CEO, the dots could well be connecting before our eyes. It would make me more certain if the trials have been completed (or even started) and we were able to re-launce with all the new labeling. My guess is that behind the scenes, there has been much more action than we know. If we are lucky, it will all be revealed within the next few weeks. Of course, I really hate depending upon luck! Thanks suebeeee1, I actually don't know odehrafe personally, (not to my knoweledge) but I agree with Sports, that he/she seems get information from possibly someone on the "Sanofi side" of the hill. I never meant to add speculation to this thread that is/was totally supported by links for verification, but the more I think about the comment about our new CEO, the more it seems to make sense. If we look at all the alliances of these innovative companies, (Insulet/Dexcom, Dexcom/Google, Sanofi/Mannkind, and Sanofi/Google), all with the same goal, (making life better for PWD), are we to assume that this is just coincidence, or is there something very special happening here ?? I DO believe this new CEO was strongly recommended by possibly a group representing all of these companies, including Mannkind, and here is why. I recently shared an older article, (2013) Artificial Pancreas A Race To The Finish jdrf.org/wp-content/uploads/2013/11/MTI1310_Artificial-Pancreas_2013700119.pdfThe article talks about several Pharmaceutical Companies in a race to market an artificial pancreas system, (APS), the most amazing part of this article was that every company trying to bring the APS to market faced the same challenge, Mealtime Glucose Spikes. And the only, (and I repeat ONLY !!) mealtime insulin product that worked with these APS was Afrezza. The article clearly states that all other RAA Prandial insulin products were just too slow, (I would recommend everybody re read this article). So now fast forward to the new goals of Insulet, Dexcom, Sanofi, and Google, to provide realtime glucose data to improve the health and quality of life for PWD. The success or failure of this goal depends on the ability to quickly handle "Mealtime Glucose Spikes", at this point, there is only one mealtime insulin product capable of doing this, Afrezza !! Afrezza solves the biggest challenge faced by any company trying to be a part of the APS or trying to establish non invasive, realtime continuous glucose monitoring. Mealtime Glucose Spikes will always need special attention in my opinion, and Afrezza is the only Prandial insulin product available to handle these spikes fast enough. In my opinion, the success or failure of the goals of all these innovative companies revolves around Afrezza. The partnerships were formed, links provided, their goals are clear, and the biggest challenge in achievivg these goals is quickly handling mealtime glucose spikes, Afrezza does this effectively and consistently. So yes, in my opinion, Afrezza is here to stay, and it is totally reasonable to assume that these companies may have had someone in mind to oversee the company that holds the answer to there biggest problem. Merry Christmas to all, and good luck to all Mannkind Longs
|
|
|
Post by rockstarrick on Dec 25, 2015 21:33:37 GMT -5
oxotnik1 and odehrafe seem to be connected to SNY in some way or know people who are. They knew about the meeting in Del Mar. But not from the T1's. Someone in side SNY, so I tend to believe that SNY did pick the CEO. Over the years you get a feel for who is full of BS and who isn't. Rock is really good at weeding out the truth:-). Merry Xmas all, this will be an exciting new year! sports His post was the one i remember reading about meeting in Del Mar first also. Confirmed about a week after he posted by someone else i trust. SO much BS, its a relief to get reliable tidbits from the very few seemingly non BS posters on ymb (who also happen to be less active and only post when something of value is learned to share) Exactly, odehrafe doesn't post often, but when he/she does, it is usually accurate, not always, but I don't think anybody is batting 1000%. I couldn't imagine Sanofi not being involved in the selection, or at least approval of our new CEO.
|
|
|
Post by rockstarrick on Dec 25, 2015 21:45:54 GMT -5
Rick, You've been around long enough to trust. I'll take the odehrafe at your word even though he doesn't show up anywhere in the membership base. I would like more information as to where he gets his information about the Sanofi involvement. This is all very curious. If indeed SNY is the force behind the new CEO, the dots could well be connecting before our eyes. It would make me more certain if the trials have been completed (or even started) and we were able to re-launce with all the new labeling. My guess is that behind the scenes, there has been much more action than we know. If we are lucky, it will all be revealed within the next few weeks. Of course, I really hate depending upon luck! Thanks suebeeee1, I actually don't know odehrafe personally, (not to my knoweledge) but I agree with Sports, that he/she seems get information from possibly someone on the "Sanofi side" of the hill. I never meant to add speculation to this thread that is/was totally supported by links for verification, but the more I think about the comment about our new CEO, the more it seems to make sense. If we look at all the alliances of these innovative companies, (Insulet/Dexcom, Dexcom/Google, Sanofi/Mannkind, and Sanofi/Google), all with the same goal, (making life better for PWD), are we to assume that this is just coincidence, or is there something very special happening here ?? I DO believe this new CEO was strongly recommended by possibly a group representing all of these companies, including Mannkind, and here is why. I recently shared an older article, (2013) Artificial Pancreas A Race To The Finish jdrf.org/wp-content/uploads/2013/11/MTI1310_Artificial-Pancreas_2013700119.pdfThe article talks about several Pharmaceutical Companies in a race to market an artificial pancreas system, (APS), the most amazing part of this article was that every company trying to bring the APS to market faced the same challenge, Mealtime Glucose Spikes. And the only, (and I repeat ONLY !!) mealtime insulin product that worked with these APS was Afrezza. The article clearly states that all other RAA Prandial insulin products were just too slow, (I would recommend everybody re read this article). So now fast forward to the new goals of Insulet, Dexcom, Sanofi, and Google, to provide realtime glucose data to improve the health and quality of life for PWD. The success or failure of this goal depends on the ability to quickly handle "Mealtime Glucose Spikes", at this point, there is only one mealtime insulin product capable of doing this, Afrezza !! Afrezza solves the biggest challenge faced by any company trying to be a part of the APS or trying to establish non invasive, realtime continuous glucose monitoring. Mealtime Glucose Spikes will always need special attention in my opinion, and Afrezza is the only Prandial insulin product available to handle these spikes fast enough. In my opinion, the success or failure of the goals of all these innovative companies revolves around Afrezza. The partnerships were formed, links provided, their goals are clear, and the biggest challenge in achievivg these goals is quickly handling mealtime glucose spikes, Afrezza does this effectively and consistently. So yes, in my opinion, Afrezza is here to stay, and it is totally reasonable to assume that these companies may have had someone in mind to oversee the company that holds the answer to there biggest problem. Merry Christmas to all, and good luck to all Mannkind Longs Inhaled Insulin Studied In APS Research Another research project being watched closely comes from the Sansum Diabetes Research Institute and the University of Califor- nia, Santa Barbara (UCSB), where the still experimental inhaled insulin from MannKind Corp. is being used in an APS research trial. (See “MannKind Gears Up To Make Commercial Case For Inhaled Insulin Afrezza” — Pharma- ceutical Approvals Monthly, September 2013.) JDRF’s Kowalski told Medtech Insight the study is the only one where Afrezza (insulin human [rDNA origin]) Inhalation Powder, a fast-acting insulin, is being used in an APS. The study is investigating the use of Afrezza in conjunction with a regular basal and bolus system, and the equipment in the study includes an OmniPod patch pump from Insulet and a DexCom sen- sor. In a joint announcement with JDRF, the project’s lead researcher, Howard Zisser, MD, explained that the trial addresses one of the big questions in diabetes research: “How do we manage meals with the arti cial pancreas?” The issue is a concern, because follow- ing a meal many diabetics have a dif cult time managing their glucose levels, and the standard subcutaneous method of delivering insulin is slow compared with how fast glucos
|
|
|
Post by rockstarrick on Dec 25, 2015 21:49:04 GMT -5
Thanks suebeeee1, I actually don't know odehrafe personally, (not to my knoweledge) but I agree with Sports, that he/she seems get information from possibly someone on the "Sanofi sideline" of the hill. I never meant to add speculation to this thread that is/was totally supported by links for verification, but the more I think about the comment about our new CEO, the more it seems to make sense. If we look at all the alliances of these innovative companies, (Insulet/Dexcom, Dexcom/Google, Sanofi/Mannkind, and Sanofi/Google), all with the same goal, (making life better for PWD), are we to assume that this is just coincidence, or is there something very special happening here ?? I DO believe this new CEO was strongly recommended by possibly a group representing all of these companies, including Mannkind, and here is why. I recently shared an older article, (2013) Artificial Pancreas A Race To The Finish jdrf.org/wp-content/uploads/2013/11/MTI1310_Artificial-Pancreas_2013700119.pdfThe article talks about several Pharmaceutical Companies in a race to market an artificial pancreas system, (APS), the most amazing part of this article was that every company trying to bring the APS to market faced the same challenge, Mealtime Glucose Spikes. And the only, (and I repeat ONLY !!) mealtime insulin product that worked with these APS was Afrezza. The article clearly states that all other RAA Prandial insulin products were just too slow, (I would recommend everybody re read this article). So now fast forward to the new goals of Insulet, Dexcom, Sanofi, and Google, to provide realtime glucose data to improve the health and quality of life for PWD. The success or failure of this goal depends on the ability to quickly handle "Mealtime Glucose Spikes", at this point, there is only one mealtime insulin product capable of doing this, Afrezza !! Afrezza solves the biggest challenge faced by any company trying to be a part of the APS or trying to establish non invasive, realtime continuous glucose monitoring. Mealtime Glucose Spikes will always need special attention in my opinion, and Afrezza is the only Prandial insulin product available to handle these spikes fast enough. In my opinion, the success or failure of the goals of all these innovative companies revolves around Afrezza. The partnerships were formed, links provided, their goals are clear, and the biggest challenge in achievivg these goals is quickly handling mealtime glucose spikes, Afrezza does this effectively and consistently. So yes, in my opinion, Afrezza is here to stay, and it is totally reasonable to assume that these companies may have had someone in mind to oversee the company that holds the answer to there biggest problem. Merry Christmas to all, and good luck to all Mannkind Longs Inhaled Insulin Studied In APS Research Another research project being watched closely comes from the Sansum Diabetes Research Institute and the University of Califor- nia, Santa Barbara (UCSB), where the still experimental inhaled insulin from MannKind Corp. is being used in an APS research trial. (See “MannKind Gears Up To Make Commercial Case For Inhaled Insulin Afrezza” — Pharma- ceutical Approvals Monthly, September 2013.) JDRF’s Kowalski told Medtech Insight the study is the only one where Afrezza (insulin human [rDNA origin]) Inhalation Powder, a fast-acting insulin, is being used in an APS. The study is investigating the use of Afrezza in conjunction with a regular basal and bolus system, and the equipment in the study includes an OmniPod patch pump from Insulet and a DexCom sen- sor. In a joint announcement with JDRF, the project’s lead researcher, Howard Zisser, MD, explained that the trial addresses one of the big questions in diabetes research: “How do we manage meals with the arti cial pancreas?” The issue is a concern, because follow- ing a meal many diabetics have a dif cult time managing their glucose levels, and the standard subcutaneous method of delivering insulin is slow compared with how fast glucos Continued, appears in the bloodstream after a meal. Co- principal investigator Francis J. Doyle, III, PhD, associate dean of research engineering at UCSB, explained that using “inhaled, ultra- rapid-acting insulin, we have a chance now to manage blood glucose even better by emulat- ing a more natural pancreatic function. We can get the insulin quickly into circulation and it will be cleared quickly and safely from the bloodstream.” Research has shown a person with diabetes might see a blood glucose spike as high as 60 mg/dL after a meal, but with the fast-acting insulin that spike might be consid- erably smaller – somewhere around 20 mg/dL.
|
|
|
Post by rockstarrick on Dec 25, 2015 21:58:17 GMT -5
Inhaled Insulin Studied In APS Research Another research project being watched closely comes from the Sansum Diabetes Research Institute and the University of Califor- nia, Santa Barbara (UCSB), where the still experimental inhaled insulin from MannKind Corp. is being used in an APS research trial. (See “MannKind Gears Up To Make Commercial Case For Inhaled Insulin Afrezza” — Pharma- ceutical Approvals Monthly, September 2013.) JDRF’s Kowalski told Medtech Insight the study is the only one where Afrezza (insulin human [rDNA origin]) Inhalation Powder, a fast-acting insulin, is being used in an APS. The study is investigating the use of Afrezza in conjunction with a regular basal and bolus system, and the equipment in the study includes an OmniPod patch pump from Insulet and a DexCom sen- sor. In a joint announcement with JDRF, the project’s lead researcher, Howard Zisser, MD, explained that the trial addresses one of the big questions in diabetes research: “How do we manage meals with the arti cial pancreas?” The issue is a concern, because follow- ing a meal many diabetics have a dif cult time managing their glucose levels, and the standard subcutaneous method of delivering insulin is slow compared with how fast glucos Continued, appears in the bloodstream after a meal. Co- principal investigator Francis J. Doyle, III, PhD, associate dean of research engineering at UCSB, explained that using “inhaled, ultra- rapid-acting insulin, we have a chance now to manage blood glucose even better by emulat- ing a more natural pancreatic function. We can get the insulin quickly into circulation and it will be cleared quickly and safely from the bloodstream.” Research has shown a person with diabetes might see a blood glucose spike as high as 60 mg/dL after a meal, but with the fast-acting insulin that spike might be consid- erably smaller – somewhere around 20 mg/dL. I don't think all these dots, (clues) are a coincidence, I think PWD are going to be living better and healthier lives, and I believe Afrezza will play a huge part in it. Good Luck to all
|
|